BridgeMD
LIBERAL Study
EU CTIS ID: 2023-507823-52-00
What this study is testing
To demonstrate that a potassium-rich diet, including the use of sodium zirconium cyclosilicate (SZC) as potential rescue treatment (in case of hyperkalemia), does not result in an unacceptable rise in plasma potassium
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients (≥ 18 years)
- Chronic kidney disease stage 3b to 4 (eGFR 44 – 15 ml/min/1.73 m2)
- Use of inhibitor of the renin-angiotensin system
You likely can't join if
- Hyperkaliemia (plasma potassium > 5.5 mmol/L) at baseline or at the start of potassium enriched diet
- Kidney transplantation patients
- Patients with a life expectancy of < 6 months
- Hypersensitivity to SCZ (Sodium zirconium cyclosilicate)
- Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team
- Women who are pregnant, breastfeeding or considering pregnancy in the coming 6 months
See the full eligibility criteria
- Adult patients (≥ 18 years)
- Chronic kidney disease stage 3b to 4 (eGFR 44 – 15 ml/min/1.73 m2)
- Use of inhibitor of the renin-angiotensin system
- Hyperkaliemia (plasma potassium > 5.5 mmol/L) at baseline or at the start of potassium enriched diet
- Kidney transplantation patients
- Patients with a life expectancy of < 6 months
- Hypersensitivity to SCZ (Sodium zirconium cyclosilicate)
- Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team
- Women who are pregnant, breastfeeding or considering pregnancy in the coming 6 months
- Use of potassium binders at baseline or at the start of potassium enriched diet
- Use of dual RAAS-blockade, mineralocorticoid receptor blockers or potassium-sparing diuretics
- Use of calcineurin inhibitors
- Use of trimethoprim and sulfamethoxazole
- Patients with a previous history of ventricular cardiac arrhythmia
- Patients with a prolonged QTc time on ECG
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.